BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• AmorChem Reinforces Its Innate Immunity Franchise with an Investment in Checkpoint Control Target SRSF3

  AmorChem II is very proud to announce the financing of a new university project.

  February 11, 2019

   · 

  3 min read
• Drug Development

  Alpine Immune Sciences Announces First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program ALPN-101

  First Dual ICOS/CD28 Inhibitor to Enter Clinical Trials

  February 11, 2019

   · 

  5 min read
• Policy

  European Commission Approves Bristol-Myers Squibb’s Sprycel (dasatinib) in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

  Bristol-Myers Squibb Company announced that the European Commission has approved Sprycel in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

  February 11, 2019

   · 

  20 min read
• Business

  3SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies

  3SBio Inc. (“3SBio”) (HKEX:1530) and Verseau Therapeutics, Inc. (“Verseau”) announced today a partnership agreement focused on the development and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a broad range of cancers.

  February 11, 2019

   · 

  3 min read
• Biotech Beach

  Einstein Healthcare Network Selects Zynx Health for Evidence-Based Optimization

  Leading academic healthcare system to implement Zynx Health solutions to unify clinical content and meet organizational goals

  February 11, 2019

   · 

  5 min read
• Drug Development

  Precigen Announces Clearance of IND to Initiate Phase 1 Study for First-in-Class PRGN-3005 UltraCAR-T™ to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients

  First-in-class therapy using autologous CAR-T cells targeting advanced ovarian cancer

  February 11, 2019

   · 

  4 min read
• Genetown

  IFM Therapeutics, LLC Launches New Subsidiary, IFM Due, to Advance cGAS/STING Antagonists for Serious Inflammatory and Autoimmune Diseases

  World-renowned researcher, Andrea Ablasser, M.D., appointed IFM Due Founding Scientist and named to IFM’s Scientific Advisory Board

  February 11, 2019

   · 

  4 min read
• Deals

  Cannara Biotech Shares to Begin Trading on the Frankfurt Exchange

  Cannara Biotech Inc., a vertically integrated cannabis company focused on cultivation and cannabis-infused products, announced its common shares are listed for trading on the Frankfurt Stock Exchange under the trading symbol “8CB”.

  February 11, 2019

   · 

  2 min read
• BioForest

  Pierangeli Clinic Initiates Program Providing Neovasc Reducer™ Procedure to Italian Patients with Refractory Angina

  Second U.S. patient successfully undergoes Reducer procedure under compassionate use

  February 11, 2019

   · 

  9 min read
• Lone Star Bio

  ESSA Pharma Announces Two Abstracts Selected to be Presented at the 2019 Genitourinary Cancers Symposium

  ESSA compounds have been selected for a poster presentation at the upcoming 2019 Genitourinary Cancers Symposium to be held February 14 – 16, 2019 at the Moscone Center in San Francisco, CA.

  February 11, 2019

   · 

  5 min read